New Drug That Immediately Treats Migraines Approved by FDA

The treatment was tested on 1,439 adult patients.

Migraines are serious headaches with intense throbbing or pulsating pain often accompanied by visual disturbances that can last for hours and even days. Up to now, most of the treatments for migraines have been preventative and most of the regular treatments for headaches have failed to provide relief.


A new drug

Now, a new drug for adults called Ubrelvy (ubrogepant) that has just been approved by the Food and Drug Administration (FDA) may just change all that. “Migraine is an often disabling condition that affects an estimated 37 million people in the U.S.,” said Billy Dunn, M.D., acting director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research.

“Ubrelvy represents an important new option for the acute treatment of migraine in adults, as it is the first drug in its class approved for this indication. The FDA is pleased to approve a novel treatment for patients suffering from migraine and will continue to work with stakeholders to promote the development of new safe and effective migraine therapies.”

1,439 adult patients

Ubrelvy was tested in two randomized, double-blind, placebo-controlled studies. The trials saw 1,439 adult patients to be administered Ubrelvy to treat an ongoing migraine.

In both studies, the percentages of patients reporting that the effects of the migraine stopped two hours after taking Ubrelvy were significantly greater than those taking placebos. The drug did come with some side effects that included nausea, tiredness and dry mouth.

Migraines are difficult to treat and prevent as they can often be triggered by many factors. Stress, hormones, bright or flashing lights, lack of food or sleep, and diet can all cause migraines.

Migraines affect more than 10% of people around the world and are three times more common in women than in men. 

Follow Us on

Stay on top of the latest engineering news

Just enter your email and we’ll take care of the rest:

By subscribing, you agree to our Terms of Use and Privacy Policy. You may unsubscribe at any time.